Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma
Clinical trial NCT03282396 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03282396
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-08
- Primary completion
- 2028-02-28
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.